August 15, 2025

The Inflation Reduction Act and Ibrutinib

In August 2024, the Centers for Medicare & Medicaid Services (CMS) announced a negotiated price for the Bruton’s tyrosine kinase inhibitor ibrutinib that is 38% lower than the manufacturer’s list ...

The ASCO Post

August 15, 2025

New Report Supports Overhaul of Cancer Drug Dosing

A new study calls for a paradigm shift in how cancer drug dosages are determined, concluding that the long-standing practice of using the “maximum tolerated dose” (MTD) may be outdated, harmful to pat...

The ASCO Post

August 15, 2025

Studies Explore Cardiac Risks and Clinical Characteristics Associated With Immune Checkpoint Inhibitor–Related Myocarditis

Immune checkpoint inhibitors (ICIs) have significantly impacted treatment options for a wide range of cancers given their efficacy, especially among cancer types that are considered immunologically “h...

The ASCO Post

August 15, 2025

Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update

ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies. The update, which amends the most ...

The ASCO Post

August 15, 2025

Alcohol-Associated Cancer Death Rates Are Climbing

Alcohol-associated cancer deaths have doubled in the United States, disproportionately affecting men and those aged 55 or older, according to the results of an observational study presented at the 202...

The ASCO Post

August 14, 2025

Why Sarcomas Require Expert, Multidisciplinary Cancer Care

Sarcomas are one of the rarest and most complex cancer types, making up less than 1% of all new cancer diagnoses in the United States.

Baptist Health South Florida

August 14, 2025

Cannabis Use Disorder and Risk of Oral Cancer

Cannabis use disorder was associated with at least a threefold increase in the risk for developing oral cancer over 5 years compared with those without cannabis use disorder, according to findings fro...

The ASCO Post

August 07, 2025

DREAMM-7 Analysis Compares Survival Outcomes Between Triplet Regimens for Relapsed or Refractory Multiple Myeloma

In an analysis from the phase III DREAMM-7 trial reported in The Lancet Oncology, Hungria et al compared survival outcomes with belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bort...

The ASCO Post

August 07, 2025

Roswell Park’s Stem Cell Transplant Program Recognized by Optum as Center of Excellence

Health services leader Optum has recognized Roswell Park Comprehensive Cancer Center as a Center of Excellence (COE) for the stem cell transplant program provided through its Transplant & Cellular Therapy Center.

Roswell Park Comprehensive Cancer Center